US FDA allows expanded access to investigational drugs
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has changed its compassionate use regulations to allow seriously ill patients better access to investigational drugs when they are not eligible to participate in a clinical trial and do not have other satisfactory treatment options1.